Table 1.
Impact of multi-cohort vaccination in the Netherlands.
| Vaccination age (years) | Cancer cases prevented per vaccinated cohort | QALY gained per vaccinated cohort* | Cost difference vaccination vs no vaccination | ICER per vaccinated cohort |
|---|---|---|---|---|
| 12 | 56 | 205 | €3,672,920 | €17,907 |
| 13 | 55 | 200 | €3,675,342 | €18,342 |
| 14 | 55 | 200 | €3,675,346 | €18,343 |
| 15 | 55 | 200 | €5,589,748 | €27,925 |
| 16 | 55 | 199 | €5,559,116 | €28,027 |
| 17 | 53 | 192 | €5,594,044 | €29,169 |
| 18 | 52 | 189 | €5,595,361 | €29,575 |
| 19 | 51 | 184 | €5,597,818 | €30,361 |
| 20 | 49 | 176 | €5,601,928 | €31,771 |
| 21 | 47 | 166 | €5,607,374 | €33,850 |
| 22 | 44 | 155 | €5,612,999 | €36,296 |
| 23 | 42 | 143 | €5,618,746 | €39,182 |
| 24 | 39 | 132 | €5,624,836 | €42,774 |
| 25 | 36 | 119 | €5,631,014 | €47,147 |
| 26 | 32 | 106 | €5,637,896 | €53,173 |
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year *rounded, ICER is based on non-rounded QALY.